

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 石四藥集團有限公司 SSY Group Limited

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2005)**

## **VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT**

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug registration and drug clinical trial for Istradefylline bulk pharmaceutical and tablets respectively from the China Food and Drug Administration. Istradefylline is useful in the treatment of Parkinson’s disease and is a type 3.1 new chemical drug.

In addition, the Board also announces that the Group has obtained the approvals for drug clinical trial for Lacosamide Injection and Lacosamide Oral Solution from the China Food and Drug Administration. Lacosamide is for treatment of seizures and neuropathic pain and is a type 3.1 new chemical drug.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board  
**Chow Hing Yeung**  
*Company Secretary*

Hong Kong, 23 March 2016

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.*